Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

Open Access 01.12.2016 | special report

Soft tissue sarcomas & GIST

Highlights from ASCO meeting 2016

verfasst von: Sophie Roider-Schur, Rainer Hamacher, Thomas Brodowicz

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

Soft tissue sarcomas (STS) are a rare and heterogeneous disease sharing mesenchymal origin. While classification of different STS subtypes has generated insight into their molecular pathogenesis, treatment response, and prognosis, oncological management still poses major clinical challenges. Despite considerable evolution in definition of optimal treatment strategies over the past decade there is a critical need of new and less toxic therapeutic approaches for the treatment of metastatic sarcoma. This review covers the latest clinical study highlights for soft tissue sarcomas and gastroinestinal stromal tumours (GIST) presented at ASCO 2016, demonstrating a constant progress from conventional chemotherapy to histology-tailored therapy as well as immunotherapy approaches.
Vorheriger Artikel PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
Nächster Artikel ASCO 2016: highlights in breast cancer
Literatur
1.
Group, E.S.E.S.N.W. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–iii112.CrossRef
2.
Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21(Suppl 7):vii270–vii276.PubMed
3.
Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8 Suppl):s19–s27.CrossRef
4.
Group, E.S.E.S.N.W.. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii21–iii26.CrossRef
5.
van der Graaf WT, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.CrossRef
6.
Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.CrossRef
7.
D’Angelo SP. Manipulating the immune system with checkpoint inhibitors for patients with metastatic sarcoma. Am Soc Clin Oncol Educ Book. 2016;35:e558–e564.CrossRef
8.
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7.CrossRef
9.
Penel N. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. J Clin Oncol. 2016;34:(suppl; abstract 11003).CrossRef
10.
Schmoll HJ. Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. J Clin Oncol. 2016;34:(suppl; abstr 11003).CrossRef
11.
Tawbi HA-H. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028– A multicenter phase II study. J Clin Oncol. 2016;34:(suppl; abstr 1106).CrossRef
12.
Lin Z, et al. PD-1 antibody monotherapy for malignant melanoma: A systematic review and meta-analysis. PLOS ONE. 2016;11(8):e0160485.CrossRef
13.
George S. Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus. J Clin Oncol. 2016;34:(suppl; abstr 11007).CrossRef
14.
Von Mehren M. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J Clin Oncol. 2016;34:(suppl; abstr 11007).CrossRef
15.
DeMatteo RP, Targeting IDO. A novel immune checkpoint in GIST. oral presentation. 2016.
16.
Balachandran VP, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094–100.CrossRef
17.
Blay J‑Y. Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014. J Clin Oncol. 2016;34:(suppl; abstr 11013).CrossRef
Metadaten
Titel
Soft tissue sarcomas & GIST
Highlights from ASCO meeting 2016
verfasst von
Sophie Roider-Schur
Rainer Hamacher
Thomas Brodowicz
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0287-z

Weitere Artikel der Ausgabe 4/2016

Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

  • special report

Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation

  • short review

Short overview on the current treatment of chronic myeloid leukemia in chronic phase

  • Open Access
  • short review

Searching for the Achilles’ heel of cancer

  • editorial

Treatment of chronic myelomonocytic leukemia

  • short review

Molecular pathogenesis of chronic myelomonocytic leukemia

  • short review